Salarius closes Phase 1/2 seclidemstat Ewing sarcoma trial; explores strategic alternatives

Decoy Therapeutics Inc.

Company terminates ongoing Phase 1/2 clinical trial evaluating seclidemstat for Ewing sarcoma to conserve cash.
Board of Directors continues exploring strategic alternatives focused on maximizing shareholder value.
Still supporting MD Anderson's sponsored trial of seclidemstat + azacitidine in MDS/CMML (on partial clinical hold after grade 4 adverse event).
Warns it may need to dissolve if unable to raise capital or complete a strategic transaction soon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.